[{"address1": "117 Kendrick Street", "address2": "Suite 500", "city": "Needham", "state": "MA", "zip": "02494", "country": "United States", "phone": "781 292 4200", "website": "https://www.verastem.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.", "fullTimeEmployees": 78, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel  Calkins", "age": 36, "title": "Chief Financial Officer", "yearBorn": 1988, "fiscalYear": 2024, "totalPay": 471690, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jonathan  Pachter Ph.D.", "age": 66, "title": "Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 238176, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Julissa  Viana", "title": "Vice President of Corporate Communications & Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cathy  Carew", "title": "Chief Organizational Effectiveness Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nate  Sanburn", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Crowther", "title": "Chief Commercial & Strategy Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Colleen  Mockbee", "title": "Global Head of Regulatory Affairs & Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John  Hayslip M.D.", "age": 47, "title": "Chief Medical Officer", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 7, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 7.75, "open": 7.73, "dayLow": 7.59, "dayHigh": 8.065, "regularMarketPreviousClose": 7.75, "regularMarketOpen": 7.73, "regularMarketDayLow": 7.59, "regularMarketDayHigh": 8.065, "payoutRatio": 0.0, "beta": 0.411, "forwardPE": -4.655991, "volume": 5444919, "regularMarketVolume": 5444919, "averageVolume": 2284806, "averageVolume10days": 2159500, "averageDailyVolume10Day": 2159500, "bid": 6.15, "ask": 10.18, "bidSize": 2, "askSize": 2, "marketCap": 584481664, "fiftyTwoWeekLow": 3.46, "fiftyTwoWeekHigh": 11.25, "allTimeHigh": 225.84, "allTimeLow": 2.1, "priceToSalesTrailing12Months": 43.686497, "fiftyDayAverage": 9.0664, "twoHundredDayAverage": 7.4822, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 469952800, "profitMargins": 0.0, "floatShares": 51279966, "sharesOutstanding": 75319800, "sharesShort": 18393487, "sharesShortPriorMonth": 17632734, "sharesShortPreviousMonthDate": 1761868800, "dateShortInterest": 1764288000, "sharesPercentSharesOut": 0.2442, "heldPercentInsiders": 0.00592, "heldPercentInstitutions": 0.83192, "shortRatio": 6.89, "shortPercentOfFloat": 0.245, "impliedSharesOutstanding": 75319800, "bookValue": -0.233, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -241106000, "trailingEps": -4.28, "forwardEps": -1.66667, "lastSplitFactor": "1:12", "lastSplitDate": 1685577600, "enterpriseToRevenue": 35.126, "enterpriseToEbitda": -2.941, "52WeekChange": 0.9595959, "SandP52WeekChange": 0.14402747, "quoteType": "EQUITY", "currentPrice": 7.76, "targetHighPrice": 20.0, "targetLowPrice": 14.0, "targetMeanPrice": 16.0, "targetMedianPrice": 15.5, "recommendationMean": 1.11111, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 137706000, "totalCashPerShare": 2.062, "ebitda": -159807008, "totalDebt": 89477000, "quickRatio": 2.422, "currentRatio": 2.58, "totalRevenue": 13379000, "revenuePerShare": 0.221, "returnOnAssets": -0.66056997, "returnOnEquity": -28.88708, "grossProfits": 11391000, "freeCashflow": -80609624, "operatingCashflow": -132654000, "grossMargins": 0.85141, "ebitdaMargins": 0.0, "operatingMargins": -3.62169, "financialCurrency": "USD", "symbol": "VSTM", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "postMarketChangePercent": 4.8969088, "postMarketPrice": 8.14, "postMarketChange": 0.3800001, "regularMarketChange": 0.0100002, "regularMarketDayRange": "7.59 - 8.065", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 2284806, "fiftyTwoWeekLowChange": 4.3, "fiftyTwoWeekLowChangePercent": 1.2427746, "fiftyTwoWeekRange": "3.46 - 11.25", "fiftyTwoWeekHighChange": -3.4899998, "fiftyTwoWeekHighChangePercent": -0.3102222, "fiftyTwoWeekChangePercent": 95.959595, "earningsTimestamp": 1762263000, "earningsTimestampStart": 1762263000, "earningsTimestampEnd": 1762263000, "earningsCallTimestampStart": 1762261200, "earningsCallTimestampEnd": 1762261200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -4.28, "epsForward": -1.66667, "epsCurrentYear": -2.725, "priceEpsCurrentYear": -2.8477066, "fiftyDayAverageChange": -1.3063993, "fiftyDayAverageChangePercent": -0.14409241, "twoHundredDayAverageChange": 0.27780008, "twoHundredDayAverageChangePercent": 0.037128128, "priceToBook": -33.30472, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.1 - Strong Buy", "corporateActions": [], "postMarketTime": 1766192105, "regularMarketTime": 1766178002, "exchange": "NCM", "messageBoardId": "finmb_115881768", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.129035, "regularMarketPrice": 7.76, "shortName": "Verastem, Inc.", "longName": "Verastem, Inc.", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1327674600000, "displayName": "Verastem", "trailingPegRatio": null, "__fetch_time": "2025-12-20"}]